Animation - Understanding Biomarker Testing in Non-Small Cell Lung Cancer
This animation provides an overview of comprehensive biomarker testing for non-small cell lung cancer (NSCLC), and its critical importance for every lung cancer diagnosis. Biomarker testing shows specific mutations that drive NSCLC to grow and spread. It can also show changes in the level of a protein called PD-L1. Biomarker testing helps doctors learn about your unique type of lung cancer and how best to treat it. Watch to learn about common gene mutations EGFR, ALK, KRAS, ROS1, BRAF V600E, and others. Experts recommend that anyone diagnosed with NSCLC should have biomarker testing. If you did not receive it, talk to your doctor about biomarker testing now. This is particularly important for African Americans and other minorities who tend to have higher lung cancer rates, longer wait for care, and lower survival rates. Be sure to ask your doctor about comprehensive biomarker testing.
Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about lung cancer which will help other patients, caregivers and families.
Please rate this content:
Animation - Understanding Biomarker Testing in NSCLC
Slide Show - Understanding Biomarker Testing in NSCLC
1.
What is 'comprehensive biomarker testing'?
2.
What is a driver mutation?
3.
How is biomarker testing carried out?
4.
When should biomarker testing be done in NSCLC?
5.
Which biomarkers exist for NSCLC?
6.
What happens if my tumor tests positive? What happens if it doesn’t test positive for a biomarker?
7.
What if I have already had a biopsy and my tumor was not tested for biomarkers?
8.
What should newly diagnosed lung cancer patients do if biomarker testing is not offered to them?
9.
Why is biomarker testing so important for certain ethnic groups, such as African Americans?
10.
How can we close the gaps to make sure all NSCLC patients get tested?
